Health Canada advises that if you miss a dose and its been within 5 days, take it as soon as possible
By defining candidacy through clinical criteria rather than generalized eligibility, MEDVi positions its semaglutide program as a targeted medical solution rather than a broad consumer product
The trial was designed to evaluate the effect in this population, over a period of up to five years, of a onceweekly subcutaneously administered dose of 2.4 mg semaglutide (Wegovy) on cardiovascular outcomes compared to placebo
The side effects of these weight-loss drugs include gastrointestinal symptoms such as nausea, diarrhoea, vomiting, constipation, reduced absorption of certain foods, heartburn, indigestion, fatigue, and dehydration
The changes feel normal rather than novel
Most participants in the trial were white (61%) and women (82%)